Suppr超能文献

局部应用聚己缩胍预防出口部位感染和腹膜炎的效果:一项随机对照试验

Effect of Local Polyhexanide Application in Preventing Exit-Site Infection and Peritonitis: A Randomized Controlled Trial.

作者信息

Ceri Mevlut, Yilmaz Seref Rahmi, Unverdi Selman, Kurultak Ilhan, Duranay Murat

机构信息

Department of Nephrology, Pamukkale University Faculty of Medicine, Denizli, Turkey.

Department of Nephrology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

出版信息

Ther Apher Dial. 2020 Feb;24(1):81-84. doi: 10.1111/1744-9987.12836. Epub 2019 Jul 7.

Abstract

Topical antibiotic and antiseptic agents have been documented to reduce exit-site infection (ESI) and peritonitis in PD. The aim of this randomized controlled study was to evaluate the efficacy of polyhexanide in the prevention of ESI and peritonitis. Patients were excluded if they had active infection, > 18 years of age, ESI and peritonitis within the previous 4 weeks, received PD for less than 3-months and history of allergy to either drug. All patients were followed up until catheter removal, death, switch to dialysis, transplantation or the end of the study. ESI, tunnel infection, peritonitis, catheter removal and microorganism cause of catheter-related infection were recorded prospectively during clinic follow-up. A total of 88 patients (41 povidone-iodine group; 47 polyhexanide group) were enrolled with a total follow-up duration of 480 and 555 patient-months for povidone-iodine and alternating group, respectively. There were no significant differences in the age, sex, BMI, time of PD, rate of DM, and S. aureus carriage state. A total of 8 ESI and 25 peritonitis episodes were detected during the study. ESI and peritonitis rates tended to be lower in polyhexanide group compared with the povidone-iodine group (0.06 episodes/patient-year vs. 0.12 episodes/patient-year; 0.26 episodes/patient-year vs. 0.32 episodes/patient-year, respectively), but were not significant statistically. Moreover, catheter removal was similar in both groups (0.04 / patient-year vs. 0.05 / patient-year). Polyhexanide is efficient and safe for the prevention of ESI and peritonitis and it may be used as an alternative procedure for the care of healthy exit sites.

摘要

局部用抗生素和防腐剂已被证明可减少腹膜透析(PD)中的出口部位感染(ESI)和腹膜炎。这项随机对照研究的目的是评估聚己缩胍在预防ESI和腹膜炎方面的疗效。如果患者有活动性感染、年龄大于18岁、在过去4周内有ESI和腹膜炎、接受PD治疗少于3个月以及对任何一种药物有过敏史,则将其排除。所有患者均随访至导管拔除、死亡、转为透析、移植或研究结束。在临床随访期间前瞻性记录ESI、隧道感染、腹膜炎、导管拔除及导管相关感染的微生物病因。共纳入88例患者(聚维酮碘组41例;聚己缩胍组47例),聚维酮碘组和交替组的总随访时间分别为480和555患者月。在年龄、性别、体重指数、PD时间、糖尿病发生率和金黄色葡萄球菌携带状态方面无显著差异。研究期间共检测到8例ESI和25例腹膜炎发作。聚己缩胍组的ESI和腹膜炎发生率与聚维酮碘组相比有降低趋势(分别为0.06次/患者年 vs. 0.12次/患者年;0.26次/患者年 vs. 0.32次/患者年),但无统计学意义。此外,两组的导管拔除率相似(0.04/患者年 vs. 0.05/患者年)。聚己缩胍在预防ESI和腹膜炎方面有效且安全,可作为健康出口部位护理的替代方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验